CAJ | 학술논문

目的：观察卡培他滨联合多西他赛方案治疗晚期乳腺癌获益之后以卡培他滨单药维持治疗的疗效和安全性。方法36例晚期乳腺癌患者给予卡培他滨联合多西他赛方案化疗4~6周期，疾病控制患者进入维持治疗，采用卡培他滨单药，评价疗效和毒副反应。结果全组36例患者中，总有效率为44.4%，疾病控制率为63.9%。23例进入维持组，有效率为47.8%，疾病控制率为69.6%，中位无进展生存时间为9.5个月。1、3 a生存率分别为72.8%、36.4%，主要毒副反应为白细胞减少、肝功能异常、手足综合征、皮肤色素沉着、口腔黏膜炎，多为轻度。结论卡培他滨单药维持治疗晚期乳腺癌，疗效肯定，毒副反应可耐受。
목적：관찰잡배타빈연합다서타새방안치료만기유선암획익지후이잡배타빈단약유지치료적료효화안전성。방법36례만기유선암환자급여잡배타빈연합다서타새방안화료4~6주기，질병공제환자진입유지치료，채용잡배타빈단약，평개료효화독부반응。결과전조36례환자중，총유효솔위44.4%，질병공제솔위63.9%。23례진입유지조，유효솔위47.8%，질병공제솔위69.6%，중위무진전생존시간위9.5개월。1、3 a생존솔분별위72.8%、36.4%，주요독부반응위백세포감소、간공능이상、수족종합정、피부색소침착、구강점막염，다위경도。결론잡배타빈단약유지치료만기유선암，료효긍정，독부반응가내수。
Objective To observe the efficacy and safety of capecitabine maintenance therapy after response to capecitabine plus docetaxel in the treatment of patients with advanced breast cancer. Methods Thirty-six patients with advanced breast cancer were enrolled and included in the analysis. All the patients received 4 to 6 cycles of capecitabine plus docetaxel regimen chemotherapy,the patients with disease control would been given single-agent capecitabine maintenance therapy. Results Of the 36 patients assessable for efficacy,the overall response rate was 44. 4%,and the disease control rate was 63. 9%. Twenty-three patients received capecitabine monotherapy as main-tenance therapy. The overall response rate was 47. 8%. The disease control rate was 69. 6%. The median progres-sion-free survival was 9. 5 months. 1-and 3-year survival rate was 72. 8% and 36. 4%,respectively. The main tox-icities were leukopenia,hypohepatia,hand-foot syndrome,skin pigmentation,oral mucositis which were moderate and manageable. Conclusion Capecitabine maintenance therapy after response to capecitabine plus docetaxel got the well curative effect in the treatment of patients with advanced breast cancer and was well tolerated,it would be con-sidered as a therapeutic salvage treatment regimen for advanced breast cancer.